Prostate cancer is a major public health concern. Prostate cancer is the fourth most common cancer in both sexes combined and the second most common cancer in men.1 Approximately one man in seven will be diagnosed with prostate cancer in his lifetime.2 Approximately 70% of prostate cancer cases are low risk, yet up to 90% are treated aggressively.3
We offer a wide menu of immunohistochemistry (IHC) assays. Our portfolio of products delivers the high sensitivity and specificity you need.
Our antibodies are ready-to-use on the fully automated VENTANA BenchMark IHC/ISH staining platforms, reducing the time-to-result and resources required with manual or semi-automated solutions. We have a robust assay development program focusing on immunohistochemical staining, clinical reagents, cancer diagnostic assays and much more.
VENTANA Basal Cell Cocktail (34βE12+p63) is an antibody cocktail of p63 (4A4) and keratin (34βE12). It may be used to aid in the differentiation of benign lesions with basal cells from malignant prostate lesions lacking basal cells. For more than 15 years, basal cells have been the immunohistochemical cornerstone in the diagnosis of prostate cancer4,5
p504s (SP116) Rabbit Monoclonal Primary Antibody is directed against the p504s enzyme (also known as alpha-Methylacyl Coenzyme A racemase or AMACR). p504s is found to be overexpressed in human prostatic carcinoma, and exhibits a granular, cytoplasmic staining pattern in malignant glands and cells.15
Publications demonstrate the utility of p504s as an aid to the pathologist in recognizing small foci prostatic carcinoma when used to complement an absence of basal cell staining.16 This can be achieved in a dual stain with the Basal Cell Cocktail (34βE12 + p63) to optimize the use of limited available tissue on small focal cancer biopsies.17
NKX3.1 (EP356) Rabbit Monoclonal Primary Antibody is a sensitive and specific antibody for the detection of NKX3.1 protein. Publications demonstrate that the reliable detection of NKX3.1 may have utility in a number of clinical applications in prostatic carcinoma and breast carcinomas.9
The VENTANA anti-p63 (4A4) antibody is directed against the p63 molecule, which is highly expressed in the nuclei of human prostatic basal cells and urothelial tissues. This powerful tool can aid the pathologist in the differential diagnosis of prostate cancer in conjunction with morphological findings. Delivering consistently strong nuclear staining, this antibody may be used to aid in the differentiation of benign and malignant prostatic lesions.18-20
The ERG (EPR3864) Rabbit Monoclonal Primary Antibody is capable of detecting: Truncated ERG resulting from TMPRSS2:ERG (or other ERG gene fusions) wildtype ERG (most notably expressed in vessel endothelium).